It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Herpes simplex virus (HSV) naturally infects skin and mucosal surfaces, causing lifelong recurrent disease worldwide, with no cure or vaccine. Biomimetic human tissue and organ platforms provide attractive alternatives over animal models to recapitulate human diseases. Combining prevascularization and microfluidic approaches, we present a vascularized, three-dimensional skin-on-chip that mimics human skin architecture and is competent to immune-cell and drug perfusion. The endothelialized microvasculature embedded in a fibroblast-containing dermis responds to biological stimulation, while the cornified epidermis functions as a protective barrier. HSV infection of the skin-on-chip displays tissue-level key morphological and pathophysiological features typical of genital herpes infection in humans, including the production of proinflammatory cytokine IL-8, which triggers rapid neutrophil trans-endothelial extravasation and directional migration. Importantly, perfusion with the antiviral drug acyclovir inhibits HSV infection in a dose-dependent and time-sensitive manner. Thus, our vascularized skin-on-chip represents a promising platform for human HSV disease modeling and preclinical therapeutic evaluation.
Understanding host responses to Herpes simplex virus (HSV) in humans is challenging. Here the authors report a vascularised 3D ‘skin-on-chip’ that mimics human skin architecture and is competent to immune-cell and drug perfusion; they use this to model HSV infection.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 University of Washington School of Medicine, Department of Laboratory Medicine and Pathology, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657); Fred Hutchinson Cancer Center, Vaccine and Infectious Disease Division, Seattle, USA (GRID:grid.270240.3) (ISNI:0000 0001 2180 1622)
2 Fred Hutchinson Cancer Center, Vaccine and Infectious Disease Division, Seattle, USA (GRID:grid.270240.3) (ISNI:0000 0001 2180 1622)
3 University of Washington, Department of Bioengineering, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657); University of Washington, Institute of Stem Cell and Regenerative Medicine, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657)
4 University of Washington School of Medicine, Department of Laboratory Medicine and Pathology, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657); Fred Hutchinson Cancer Center, Vaccine and Infectious Disease Division, Seattle, USA (GRID:grid.270240.3) (ISNI:0000 0001 2180 1622); University of Washington, Institute of Stem Cell and Regenerative Medicine, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657)